MedPage Today February 25, 2025
— A lot of people want access to blockbuster therapies but can’t get it
Supplies of high-demand obesity treatments are improvingopens in a new tab or window, but that doesn’t mean it’s easier to get them.
Many employers and insurers are scaling back coverage of semaglutide (Wegovy) and tirzepatide (Zepbound) and a key government program, Medicare, doesn’t cover the drugs for obesityopens in a new tab or window. Meanwhile, some big employers are adding coverage, but their commitment isn’t guaranteed.
Treatment prices that can top hundreds of dollars monthly even after discounts make it hard for many people to afford these drugs on their own. That can make the life-changing weight loss that patients seek dependent on the coverage they...
Today's Sponsors
Today's Sponsor